BIOMAT Database Logo BIOMAT Database Logo

Inverse correlation between expression of multidrug resistance gene and N-myc oncogene in human neuroblastomas. 1990

A Nakagawara, and K Kadomatsu, and S Sato, and K Kohno, and H Takano, and K Akazawa, and Y Nose, and M Kuwano
Department of Pediatric Surgery, Faculty of Medicine, Kyushu University 60, Fukuoka, Japan.

Genomic amplification of N-myc is an important prognostic indicator in neuroblastoma. The tumors with amplified N-myc are initially sensitive to chemotherapy but often acquire resistance to therapy, recur, and ultimately kill the patients. We measured amplification and expression of N-myc and expression of mdr-1 in 35 surgically resected neuroblastomas, before acquisition of drug resistance and in 4 recurrent tumors resistant to chemotherapy. The mdr-1 mRNA expression was found to be inversely correlated with the N-myc expression. The mdr-1 gene expression was at a low level in advanced stage and histologically undifferentiated neuroblastomas, the same group of tumors in which N-myc expression is elevated. A significantly better prognosis was noted in those patients whose tumors had a high level of mdr-1 expression and a low level of N-myc expression. The role, if any, of increased expression of mdr-1 in the acquisition of multidrug resistance in neuroblastoma remains unclear. However, the aggressive clinical behavior associated with N-myc amplification and/or expression appears to be linked to down-regulation of mdr-1 expression.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D009447 Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51) Neuroblastomas
D009857 Oncogenes Genes whose gain-of-function alterations lead to NEOPLASTIC CELL TRANSFORMATION. They include, for example, genes for activators or stimulators of CELL PROLIFERATION such as growth factors, growth factor receptors, protein kinases, signal transducers, nuclear phosphoproteins, and transcription factors. A prefix of "v-" before oncogene symbols indicates oncogenes captured and transmitted by RETROVIRUSES; the prefix "c-" before the gene symbol of an oncogene indicates it is the cellular homolog (PROTO-ONCOGENES) of a v-oncogene. Transforming Genes,Oncogene,Transforming Gene,Gene, Transforming,Genes, Transforming
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D005784 Gene Amplification A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication. Amplification, Gene

Related Publications

A Nakagawara, and K Kadomatsu, and S Sato, and K Kohno, and H Takano, and K Akazawa, and Y Nose, and M Kuwano
Inverse relationship between trk expression and N-myc amplification in human neuroblastomas.
March 1992, Cancer research,
A Nakagawara, and K Kadomatsu, and S Sato, and K Kohno, and H Takano, and K Akazawa, and Y Nose, and M Kuwano
[Amplification of oncogene N-myc in human neuroblastomas].
April 1987, Gan no rinsho. Japan journal of cancer clinics,
A Nakagawara, and K Kadomatsu, and S Sato, and K Kohno, and H Takano, and K Akazawa, and Y Nose, and M Kuwano
Expression of neuronal src mRNA as a favorable marker and inverse correlation to N-myc gene amplification in human neuroblastomas.
September 1994, International journal of cancer,
A Nakagawara, and K Kadomatsu, and S Sato, and K Kohno, and H Takano, and K Akazawa, and Y Nose, and M Kuwano
Amplified allele of the human N-myc oncogene in neuroblastomas.
June 1988, Japanese journal of cancer research : Gann,
A Nakagawara, and K Kadomatsu, and S Sato, and K Kohno, and H Takano, and K Akazawa, and Y Nose, and M Kuwano
Activated expression of the N-myc gene in human neuroblastomas and related tumors.
December 1984, Science (New York, N.Y.),
A Nakagawara, and K Kadomatsu, and S Sato, and K Kohno, and H Takano, and K Akazawa, and Y Nose, and M Kuwano
Expression of the multidrug resistance, MDR1, gene in neuroblastomas.
January 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
A Nakagawara, and K Kadomatsu, and S Sato, and K Kohno, and H Takano, and K Akazawa, and Y Nose, and M Kuwano
Expression of N-myc by neuroblastomas with one or multiple copies of the oncogene.
January 1988, Progress in clinical and biological research,
A Nakagawara, and K Kadomatsu, and S Sato, and K Kohno, and H Takano, and K Akazawa, and Y Nose, and M Kuwano
Correlative patterns between cellular DNA content, N-myc oncogene amplification, and karyotypic abnormalities in human neuroblastomas. A preliminary report.
March 1993, Annals of the New York Academy of Sciences,
A Nakagawara, and K Kadomatsu, and S Sato, and K Kohno, and H Takano, and K Akazawa, and Y Nose, and M Kuwano
Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma.
October 1994, Cancer research,
A Nakagawara, and K Kadomatsu, and S Sato, and K Kohno, and H Takano, and K Akazawa, and Y Nose, and M Kuwano
Expression of multiple drug resistance gene, MDR1, and N-myc oncogene in an Italian population of human neuroblastoma patients.
January 1990, Anticancer research,
Copied contents to your clipboard!